Prior to founding ImmBio, Dr Colaço was Director of Intellectual Property (IP) for the biotechnology company Quadrant Healthcare plc, where he was responsible for development of the IP portfolio that formed the basis of its successful listing on the London Stock Exchange and acquisition by Elan. Dr Colaço was responsible for generating the IP that formed their biomolecule stabilisation and delivery technology. In addition to his industry experience, Dr Colaço has worked in a number of leading instituations, including the University of Cambridge Medical School. He has a degree in Biochemistry from the University of London and PhD from the National Institute of Medical Research, London.
The immunobiology of immunotherapy
Cancer Immunotherapy is a paradigm shift in cancer treatment which is now being recognised as a potentially curative treatment. Dr Colaco will summarise current approaches and present the approach to effective personalised cell-based cancer immunotherapy being initiated in Cambridge.
EVEN MORE SEMINARS
Glenn Flux Royal Marsden Hospital
The emergence and resurgence of radiotherapeutics for cancer treatment
Nizar Asadi Royal Brompton & Harefield NHS Foundation Trust
Thoracic surgery in the treatment of lung cancer
Dr Ndaba Mazibuko Care Oncology Clinic, Kings College London
Drug Repurposing In Practice: Metabolic Pleiotropism in Glioblastoma Management
Philip Beer MRCP, FRCPath, PhD ONCODNA S.A
The evolution of oncology therapeutics in the genomic era.
Michael Schreiber Brain Tumor Foundation, Chairman
Brain Tumors - Innovation, support and advocacy